AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders |
Akebia Therapeutics, Inc. (the Company) held its 2017 Annual
Meeting of Stockholders on June15, 2017. The stockholders
(i)elected three directors to the Board of Directors (the Board)
to serve for three-year terms expiring in 2020; and (ii)ratified
the selection of Ernst Young LLP as the Companys independent
registered public accounting firm for fiscal year 2017. There
were 38,829,563 outstanding shares eligible to vote as of
April13, 2017, the record date for the 2017 Annual Meeting.
The directors elected to the Board for terms expiring at the
Annual Meeting in 2020, as well as the number of votes for, votes
withheld and broker non-votes with respect to each of these
individuals, are set forth below:
|
|
Votes For |
VotesWithheld |
BrokerNon-Votes |
|||||||||
|
|
19,913,956 | 2,475,678 | 12,163,493 | |||||||||
|
|
19,260,931 | 3,128,703 | 12,163,493 | |||||||||
|
|
19,874,142 | 2,515,492 | 12,163,493 |
The proposal to ratify the selection of Ernst Young LLP as the
Companys independent registered public accounting firm for fiscal
year 2017 received the following votes:
|
|
34,499,773 | |||
|
|
31,639 | |||
|
|
21,715 |
About AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA)
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.